Breaking News

Financial Report: Lilly

January 28, 2016

Novartis Animal Health revenues drive growth in the quarter

4Q Revenues: $5.4 billion (+5%)

4Q Earnings: $478.4 million (+12%)

FY Revenues: $20.0 billion (+2%)

FY Earnings: $2.4 billion (+1%)

Comments: Revenue in the U.S. increased 15% to $2.8 billion in the quarter. Growth in the quarter was primarily due to the inclusion of Novartis Animal Health revenue ($811.7 million, up 28%) and diabetes drugs Trulicity ($112.5 million), and Cyramza ($117.5 million), as well as Erbitux ($176.2 million, up 83%) due to the transfer of commercialization rights in North America. These increases were partially offset by the residual impact of the loss of exclusivity for Cymbalta ($223.6 million, down 39%). Humalog sales were up 10% to $798.7 million. Alimta sales were $627.2 million down 13%. Cialis sales were $638.4 million, up 3%. Forteo sales were $377.9 million, down 1%. Humulin sales were $358.6 million, down 9%. Strattera sales were up 14% to $221.6 million.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments